Resources
Resources
Controlled resources about Vanguard Biotech Systems and NextGenAMR, drawn only from approved content. Each item answers a real question for a specific audience.
How to describe VBS and NextGenAMR
A precise-language guide for journalists, partners and analysts: the approved way to describe Vanguard Biotech Systems and NextGenAMR, and the descriptions to avoid.
- For:
- press, partners, procurement, investors
- Version:
- 1.0.0
- Updated:
- 2026-07-24
Company and product
Vanguard Biotech Systems (VBS) is the company; NextGenAMR is its first product. Present VBS as the entity and NextGenAMR as a product of VBS — not the other way round.
Describe NextGenAMR as a genomic antimicrobial-resistance intelligence platform in development by Vanguard Biotech Systems. It is not for clinical use and has no regulatory authorisation or declaration of conformity for clinical diagnostic use.
Please do not describe it as
Do not present NextGenAMR as an autonomous diagnostic system, as a tool that selects or recommends treatment, or as a replacement for phenotypic antimicrobial susceptibility testing (AST). It supports professional interpretation; it does not replace it.
Avoid performance or time-saving claims: no performance results have been published for NextGenAMR's current evidence-grade engine.
Corporate boilerplate & company facts
The approved corporate boilerplate and basic company facts, ready to quote accurately.
- For:
- press, investors, partners
- Version:
- 1.0.0
- Updated:
- 2026-07-24
Boilerplate
Vanguard Biotech Systems is a Spanish biotechnology software company developing genomic intelligence systems for antimicrobial resistance. It was incorporated as a Sociedad de Responsabilidad Limitada (S.L.) in 2025, with its operational base in Granada and its registered office in Lepe, Huelva. NextGenAMR is the first product developed by Vanguard Biotech Systems. Juan Manuel Gómez Vargas — Founder of Vanguard Biotech Systems; leads NextGenAMR development.
Company facts
Founder: Juan Manuel Gómez Vargas. Incorporated in 2025 (registered office: Lepe, Huelva); operational base: Granada, Spain. First product: NextGenAMR (in development). For registered corporate identification, see the legal notice.
Further technical documents
Additional technical documents (technical overview, genotype vs phenotype, provenance, abstention, WGS data preparation, validation protocol summary, data flow) are planned and will be released only after competent scientific review.